| scholarly article | Q13442814 |
| P5530 | Altmetric DOI | 10.1007/S12265-015-9655-Z |
| P6179 | Dimensions Publication ID | 1047584932 |
| P356 | DOI | 10.1007/S12265-015-9655-Z |
| P698 | PubMed publication ID | 26385009 |
| P1154 | Scopus EID | 2-s2.0-84947488811 |
| P50 | author | Sreenivasan Ponnambalam | Q38801053 |
| Stephen Wheatcroft | Q43402450 | ||
| David A Russell | Q52852593 | ||
| P2093 | author name string | Sreenivasan Ponnambalam | |
| Shervanthi Homer-Vanniasinkam | |||
| Izma Abdul Zani | |||
| Jonathan De Siqueira | |||
| P2860 | cites work | An endothelial receptor for oxidized low-density lipoprotein | Q24323462 |
| Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor | Q24531178 | ||
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | Q28239197 | ||
| Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation | Q28566134 | ||
| LOX-1 inhibition in myocardial ischemia-reperfusion injury: modulation of MMP-1 and inflammation | Q28583634 | ||
| Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance | Q30434516 | ||
| Role of LOX-1 and ROS in oxidized low-density lipoprotein induced epithelial-mesenchymal transition of NRK52E | Q30990551 | ||
| Significance of soluble lectin-like oxidized LDL receptor-1 levels in systemic and coronary circulation in acute coronary syndrome. | Q33660782 | ||
| Effects of clopidogrel added to aspirin in patients with recent lacunar stroke | Q33792318 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease | Q33976286 | ||
| LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. | Q34079451 | ||
| Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial | Q34092311 | ||
| OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling | Q34543359 | ||
| High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial | Q34562602 | ||
| Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque | Q35151273 | ||
| The oxidized low-density lipoprotein receptor mediates vascular effects of inhaled vehicle emissions | Q35212599 | ||
| Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: possible implications in the process of trophoblast apoptosis. | Q53626605 | ||
| Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). | Q54005785 | ||
| Blockade of LOX-1 prevents endotoxin-induced acute lung inflammation and injury in mice. | Q55224652 | ||
| Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction | Q73158540 | ||
| Identification of soluble forms of lectin-like oxidized LDL receptor-1 | Q73536903 | ||
| LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria | Q73720901 | ||
| Transforming growth factor-beta(1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1 | Q73838277 | ||
| Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results | Q77557098 | ||
| Lectin-like oxidized low-density lipoprotein receptor 1 mediates leukocyte infiltration and articular cartilage destruction in rat zymosan-induced arthritis | Q78301208 | ||
| Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage | Q80969872 | ||
| Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis | Q80976759 | ||
| Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells | Q81296828 | ||
| Lectin-like oxidized low-density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis | Q82470746 | ||
| Serum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndrome | Q82753008 | ||
| Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome--comparison with other biomarkers | Q84531189 | ||
| Protein kinase C-alpha activation induces NF-kB-dependent VCAM-1 expression in cultured human umbilical vein endothelial cells treated with sera from preeclamptic patients | Q84956624 | ||
| Monoclonal antibodies: magic bullets with a hefty price tag | Q85648827 | ||
| Endothelial damage in white coat hypertension: role of lectin-like oxidized low-density lipoprotein-1 | Q87374197 | ||
| Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome | Q87814798 | ||
| Inhibition of lectin-like oxidized low-density lipoprotein receptor-1 reduces leukocyte adhesion within the intestinal microcirculation in experimental endotoxemia in rats. | Q35561312 | ||
| Pharmacokinetics of therapeutic monoclonal antibodies used in oncology | Q36218497 | ||
| Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women | Q37181325 | ||
| Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies | Q37379764 | ||
| The safety and side effects of monoclonal antibodies | Q37715703 | ||
| Lifestyle and cardiovascular disease in Japan | Q37838640 | ||
| LOX-1 and angiotensin receptors, and their interplay | Q37921158 | ||
| Lectin-like oxidized low-density lipoprotein receptor 1 pathways. | Q38099693 | ||
| Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. | Q38464443 | ||
| CRP is a novel ligand for the oxidized LDL receptor LOX-1. | Q39878373 | ||
| LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. | Q39915945 | ||
| Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations | Q40055172 | ||
| LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells | Q40376526 | ||
| Oxidized low density lipoprotein induces apoptosis via generation of reactive oxygen species in vascular smooth muscle cells | Q42497396 | ||
| Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells | Q43633677 | ||
| PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. | Q43711390 | ||
| Lectin-like oxidized low-density lipoprotein receptor-1 plays an important role in vascular inflammation in current smokers | Q43975643 | ||
| Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). | Q44071979 | ||
| Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders | Q44150789 | ||
| LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells | Q44302094 | ||
| Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells | Q44698977 | ||
| Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet | Q45867832 | ||
| Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. | Q45953889 | ||
| Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque | Q46365505 | ||
| Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). | Q46565716 | ||
| LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet | Q46614178 | ||
| Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus | Q46648050 | ||
| Simulative and experimental investigation on the cleavage site that generates the soluble human LOX-1. | Q46930171 | ||
| Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human articular chondrocytes. | Q46987456 | ||
| Expression of lectin-like oxidized LDL receptor-1 in smooth muscle cells after vascular injury | Q47650458 | ||
| Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy | Q48732854 | ||
| LOX-1 mediates vascular lipid retention under hypertensive state. | Q50446964 | ||
| LOX-1 is a novel therapeutic target in neonatal hypoxic-ischemic encephalopathy. | Q50648730 | ||
| Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnostic marker for rupture of thin-cap fibroatheroma: verification by optical coherence tomography. | Q51029154 | ||
| Oxidized LDL receptor LOX-1 is involved in neointimal hyperplasia after balloon arterial injury in a rat model. | Q51813661 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 458-465 | |
| P577 | publication date | 2015-09-18 | |
| P1433 | published in | Journal of Cardiovascular Translational Research | Q6294906 |
| P1476 | title | Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics | |
| P478 | volume | 8 |
| Q33564156 | Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. | cites work | P2860 |
Search more.